British Watchdog Rejects GSKs Lupus Drug AgainBritish Watchdog Rejects GSKs Lupus Drug Again

Britain's healthcare cost watchdog has rejected GlaxoSmithKline's lupus drug belimumab (Benlysta) a second time after the company offered an undisclosed discount, saying it still failed to offer good value for money. Reuters Health Information

Source: Medscape Medical News Headlines - July 24, 2013 Category: Consumer Health News Tags: Rheumatology News Source Type: news